Summary
The AI-generated claims include multiple efficacy/percent-response statements and safety statements that cannot be verified against the provided FDA label excerpts. Only general label elements (e.g., infections, hypersensitivity, TB evaluation, IBD risk, adverse reactions categories) are present, but the specific quantitative efficacy claims and several safety detail claims are not supported by the supplied text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication that targets the interleukin-17A (IL-17A) protein.
Supported conceptually by provided label excerpt: secukinumab is described as an IL-17A antagonist (Drug/Active ingredient section provided in prompt).
Cosentyx is approved for the treatment of psoriasis.
Supported at least at the level of 'moderate to severe plaque psoriasis' in the provided Indications and Usage excerpt.
Cosentyx is approved for the treatment of psoriatic arthritis.
Supported by provided Indications and Usage excerpt listing psoriatic arthritis.
Cosentyx is approved for the treatment of ankylosing spondylitis.
Supported by provided Indications and Usage excerpt listing ankylosing spondylitis.
Cosentyx can cause injection site reactions.
Not directly supported by the provided label excerpts. (No explicit injection-site adverse reaction text was included in the supplied excerpt.)
Unsupported Statements
By blocking IL-17A, Cosentyx reduces inflammation and prevents the immune system from attacking healthy tissues.
No explicit mechanistic/efficacy phrasing matching this claim is present in the supplied excerpts.
Cosentyx is administered via injection.
No administration route detail was included in the supplied excerpts.
Cosentyx is approved for the treatment of plaque psoriasis.
While 'moderate to severe plaque psoriasis' appears in the provided Indications/Usage excerpt, the claim omits the 'moderate to severe' qualifier; the provided excerpts do not show whether approval is limited to that qualifier beyond the excerpt wording.
Cosentyx works by binding to IL-17A, preventing it from interacting with its receptor on immune cells.
No explicit receptor-binding/interference mechanism statement is provided in the supplied excerpts.
By blocking IL-17A, Cosentyx reduces the production of pro-inflammatory cytokines.
No explicit statement about reducing pro-inflammatory cytokine production is provided in the supplied excerpts.
Cosentyx reduces psoriasis symptoms by 75% or more in 60% of patients.
No efficacy quantitative results (e.g., 75% response in 60% of patients) are provided in the supplied excerpts.
Cosentyx has been shown to be highly effective in treating psoriasis.
No comparative efficacy statements or trial outcomes are provided in the supplied excerpts.
Cosentyx reduces joint pain and swelling by 50% or more in 60% of patients with psoriatic arthritis.
No quantitative efficacy results for psoriatic arthritis are provided in the supplied excerpts.
Cosentyx has been shown to be effective in treating psoriatic arthritis.
No efficacy evidence text is provided in the supplied excerpts.
Cosentyx reduces joint pain and stiffness by 50% or more in 60% of patients with ankylosing spondylitis.
No quantitative efficacy results for ankylosing spondylitis are provided in the supplied excerpts.
Cosentyx has been shown to be effective in treating ankylosing spondylitis.
No efficacy evidence text is provided in the supplied excerpts.
Cosentyx reduces plaque psoriasis symptoms by 75% or more in 60% of patients.
No quantitative efficacy results for plaque psoriasis are provided in the supplied excerpts.
Cosentyx has been shown to be highly effective in treating plaque psoriasis.
No efficacy evidence text is provided in the supplied excerpts.
Cosentyx can cause upper respiratory tract infections.
Supported generally by the 'Infections' warning excerpt mentioning increased upper respiratory tract infection rates, but the claim is not specific enough to verify without the exact context/wording. Treated here as unsupported for this scoring because the provided excerpt is not explicitly mapped to an adverse reaction list item.
Cosentyx can cause nausea.
No nausea adverse reaction statement is present in the provided excerpts.
The side effects of Cosentyx are generally mild and temporary.
No statement about side effect severity/mildness/temporariness is provided in the supplied excerpts.
Most patients are able to continue treatment with Cosentyx without significant issues.
No label text about discontinuation rates or continuation without issues is provided in the supplied excerpts.
Contradictions
Important Omissions
No label-accurate safety counseling details were included for infections (e.g., seek medical advice for infection symptoms, monitor/ discontinue for serious infection, TB screening, avoidance in active TB, caution in chronic/recurrent infections).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several claims include unverified quantitative efficacy outcomes and generalized safety statements (e.g., mild/temporary side effects, most patients continue without issues) not supported by the provided excerpts. Additionally, specific adverse reaction claims (e.g., nausea) are not supported, which could mislead safety expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many efficacy quantifications and multiple safety/administration/mechanism assertions are not supported by the provided FDA label excerpts.
Suggested Improvement
Replace quantitative efficacy statements and mechanistic explanations with exact label-supported efficacy endpoints and wording. Limit safety statements to those explicitly present in the supplied label excerpts (e.g., infection risk details, hypersensitivity reactions, TB evaluation, IBD/exacerbations). Include label-supported administration/route and any required safety monitoring language.